Background To manage severe or potentially severe cases of CoronaVirus Disease 2019 (COVID-19), therapeutic monoclonal antibodies targeting Spike protein of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) have been designed. It has been noted in vitro that upon exposure to these treatments, mutations could be selected. Case presentation We here report the case of an immunosuppressed patient infected with a B.1.1.7 variant, who received a combination of monoclonal antibodies, and subsequently selected mutations K417N, E484K and Q493R on Spike protein of SARS-CoV-2. Conclusions Our case raises the importance of monitoring SARS-CoV-2 mutations in patients receiving monoclonal antibodies and having persistent excretion of the virus, in order to offer optimal management of their infection, and strengthen prevention measures to avoid subsequent transmission of these selected variants.
【저자키워드】 SARS-CoV-2, monoclonal antibodies, Case report, Resistance mutations selection, 【초록키워드】 COVID-19, coronavirus disease, Coronavirus disease 2019, Mutation, spike, monoclonal antibody, Infection, Transmission, severe acute respiratory syndrome coronavirus-2, in vitro, severe acute respiratory syndrome Coronavirus, monoclonal antibodies, virus, variants, Spike protein, Severe acute respiratory syndrome, Protein, B.1.1.7 variant, B.1.1.7, K417N, management, therapeutic, Patient, E484K, SARS-CoV-2 mutations, SARS-CoV-2 mutation, respiratory, Combination, Immunosuppressed, exposure to, measure, Severe case, offer, raise, selected, subsequent, receiving, 【제목키워드】 Mutation, emergence, Patient, monoclonal,